Internal Reference Number: FOI_6541
Date Request Received: 01/04/2022 00:00:00
Date Request Replied To: 07/04/2022 00:00:00
This response was sent via: By Email
Request Summary: Lung Cancer Treatment
Request Category: Private Individuals
| Question Number 1: In the past 3 months (or the latest 3 months data you have available), how many metastatic non-small cell lung cancer (NSCLC) patients were treated with any of the following: • Afatinib • Alectinib • Atezolizumab monotherapy • Atezolizumab in combination • Bevacizumab • Brigatinib • Capmatenib • Ceritinib • Crizotinib • Dacomitinib • Dabrafenib with Trametinib • Docetaxel monotherapy • Durvalumab • Erlotinib • Gefitinib • Gemcitabine • Nintedanib with Docetaxel • Nivolumab • Osimertinib • Paclitaxel • Pembrolizumab monotherapy • Pembrolizumab in combination • Pemetrexed with Carboplatin/Cisplatin • Tepotinib • Vinorelbine with Cisplatin/Carboplatin • Any other SACT • Palliative care only | |
| Answer To Question 1: Afatinib 0 • Alectinib <5 • Atezolizumab monotherapy <5 • Atezolizumab in combination <5 • Bevacizumab 0 • Brigatinib 0 • Capmatenib 0 • Ceritinib 0 • Crizotinib <5 • Dacomitinib 0 • Dabrafenib with Trametinib 0 • Docetaxel monotherapy 0 • Durvalumab <5 • Erlotinib 0 • Gefitinib <5 • Gemcitabine 0 • Nintedanib with Docetaxel 0 • Nivolumab 0 • Osimertinib 10 • Paclitaxel 0 • Pembrolizumab monotherapy <5 • Pembrolizumab in combination <5 • Pemetrexed with Carboplatin/Cisplatin 7 • Tepotinib 0 • Vinorelbine with Cisplatin/Carboplatin <5 • Any other SACT 9 • Palliative care only | |
| To return to the list of all the FOI requests please click here |
Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of ¿´Æ¬Èí¼þ Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
